Heartwood Wealth Advisors LLC Sells 1,245 Shares of Pfizer Inc. (NYSE:PFE)

Heartwood Wealth Advisors LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,231 shares of the biopharmaceutical company’s stock after selling 1,245 shares during the quarter. Heartwood Wealth Advisors LLC’s holdings in Pfizer were worth $383,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of PFE. Cheviot Value Management LLC boosted its position in Pfizer by 6.5% in the fourth quarter. Cheviot Value Management LLC now owns 325,594 shares of the biopharmaceutical company’s stock valued at $9,448,000 after buying an additional 19,843 shares in the last quarter. Bellevue Group AG boosted its holdings in shares of Pfizer by 139.3% during the 4th quarter. Bellevue Group AG now owns 22,868 shares of the biopharmaceutical company’s stock valued at $658,000 after acquiring an additional 13,313 shares in the last quarter. Wasatch Advisors LP grew its position in Pfizer by 21.0% during the 4th quarter. Wasatch Advisors LP now owns 167,300 shares of the biopharmaceutical company’s stock worth $4,817,000 after acquiring an additional 29,000 shares during the last quarter. Mmbg Investment Advisors CO. increased its holdings in Pfizer by 13.5% in the 4th quarter. Mmbg Investment Advisors CO. now owns 157,855 shares of the biopharmaceutical company’s stock worth $4,545,000 after purchasing an additional 18,730 shares in the last quarter. Finally, MGO One Seven LLC raised its position in Pfizer by 43.0% in the fourth quarter. MGO One Seven LLC now owns 120,715 shares of the biopharmaceutical company’s stock valued at $3,475,000 after purchasing an additional 36,316 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE opened at $29.19 on Tuesday. The firm has a market cap of $165.41 billion, a PE ratio of -486.50, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $33.92. The business’s 50 day moving average price is $29.17 and its two-hundred day moving average price is $28.32. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter in the previous year, the company earned $0.67 EPS. Pfizer’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Analysts Set New Price Targets

PFE has been the topic of several research reports. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Barclays increased their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.